AbCellera Biologics (NASDAQ: ABCL) announced positive topline Phase 2 results for ABCL635, demonstrating significant reductions in the frequency and severity of vasomotor symptoms, along with a favorable tolerability profile. Sector: Biotechnology Key Highlights 🧬 Positive Phase 2 results for ABCL635 📉 Significant reduction in symptom frequency and severity ✅ Favorable tolerability profile 🚀 Supports continued development of ABCL635 Why It Matters The positive clinical data strengthens AbCellera's pipeline and supports the potential of ABCL635 as a treatment for vasomotor symptoms. Read More: https://www.thinksabio.com/reports/isr/ABCL